| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $10.6M | — | -7.2% |
| SG&A Expense | $4.7M | — | +16.9% |
| Operating Income | -$15.3M | — | +1.0% |
| Net Income | -$13.5M | — | +10.5% |
| EPS (Basic) | -$0.21 | — | +50.0% |
| EPS (Diluted) | -$0.21 | — | +50.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $47.3M | -63.2% | +31.9% |
| Current Assets | $161.4M | -8.4% | +322.5% |
| Total Assets | $214.8M | -7.4% | +323.8% |
| Current Liabilities | $5.0M | -50.6% | -2.6% |
| Total Liabilities | $8.3M | -38.6% | -6.2% |
| Stockholders' Equity | $206.5M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$18.4M | — | -30.9% |
| Capital Expenditures | $80K | — | +793.6% |
| Investing Cash Flow | -$63.1M | — | — |
| Financing Cash Flow | $181K | — | -98.7% |
| Free Cash Flow | -$18.5M | — | -31.4% |
| +393.6% |